Breaking News

FDA Selects ICON to Validate PROs

Will measure clinical endpoints in antibacterial drug trials

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ICON plc has been selected by the U.S. FDA to validate three Patient Reported Outcomes (PRO) instruments that will measure clinical endpoints in antibacterial drug trials. This is the 2nd time ICON has been selected by the FDA to create industry-standard PRO measures.   The endpoints to be validated are Acute Bacterial Skin and Skin Structure Infections (ABSSSI), Community-Acquired Bacterial Pneumonia (CABP) and Hospital-Acquired Bacterial Pneumonia (HABP). Currently, there are no qualified PR...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters